Streetwise Reports' Article Archives — October 2019 back to current month (34)
The Canadian company will provide its remote patient monitoring and chronic care management software solutions to these two U.S. enterprises.
Shares of Navidea Biopharmaceuticals traded 60% higher today on extremely high relative volume after the firm released data from its Phase 2b Rheumatoid Arthritis Tc 99m Tilmanocept Planar Imaging study.
The recent results and their implications are provided in an H.C. Wainwright & Co. report.
The package encompasses wearable devices, two-way video communication and geofencing.
Shares of IVERIC bio opened nearly 100% higher today after reporting that it successfully met its primary endpoint in its Phase 2b age-related macular degeneration study for Zimura.
Shares of respiratory medical device maker and software applications company ResMed Inc. traded 15% higher at times today after the firm posted positive Q1/20 earnings results.
Shares of Varian Medical Systems traded 10% higher at times today after the company reported quarterly and annual earnings. The company increased revenue 10% year-over-year and provided FY/20 guidance.
The results and commercial potential of the therapeutic are discussed in an H.C. Wainwright & Co. report.
The primary aim of the firm's technology platform is to support remote patient monitoring.
These therapeutic candidates add to those already in the firm's pipeline.
This morning shares of Boston Scientific traded 6% higher after the firm reported a 13.1% increase in revenue for Q3/19. The firm also raised its revenue guidance for both Q4/19 and FY/19.
Shares of Biogen Inc. opened nearly 39% higher today after the firm announced plans to submit a Biologics License Application to the FDA in early 2020 for its Alzheimer's drug aducanumab based on new analysis of larger datasets from two phase 3 studies. The company also announced Q3/19 earnings today.
The details of this study and a second one are outlined in a ROTH Capital Partners report.
Dermira shares traded higher today after the firm released positive data from its phase 2b study of lebrikizumab in patients with atopic dermatitis at the Las Vegas Fall Clinical Dermatology Conference.
Shares of Protalix Biotherapeutics skyrocketed today on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease.
Healthcare Tech Firm Signs Five New Clients in Texas (10/16/2019)
The company just landed another five clients in Texas and now plans to build out sales teams in five additional states.
Shares of Achillion Pharmaceuticals are trading much higher today after the firm reported that it has agreed to be acquired by Alexion Pharmaceuticals for $930 million, or $6.30 per share in cash, along with the potential for an additional $2 per share if certain other specific clinical trial and regulatory milestones are met.
Good news is piling up for this healthcare stock engaged in the treatment of hepatitis B as it trades at 5X its average volume with a 30% stock price gain over previous close.
The goal is to reduce the time healthcare workers spend on mundane tasks and thereby improve patient care.
Shares of Relmada Therapeutics have traded wildly today after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100–200% higher today and the stock was halted several times trading due to extreme price volatility.
Technical analyst Clive Maund outlines the reasons this stock might break higher.
Shares of Cerecor Inc. are trading higher today after reporting that it will sell its pediatric portfolio to Aytu BioScience for $32 million in a combination cash and stock deal.
Technical analyst Clive Maund believes this stock could gain traction soon.
Shares of Reata Pharmaceuticals are trading 12% higher today after the firm announced it had reacquired all licensing rights in the U.S. for bardoxolone methyl and worldwide rights for omaveloxolone and other next-generation Nrf2 activators from AbbVie.
Shares of Ra Pharmaceuticals doubled today after the firm announced that it will be acquired by Belgian firm UCB for $48 per share in an all cash deal.
Soliton Inc. shares traded 10% higher today after advising that later this month it will present the data from clinical trials for its Rapid Acoustic Pulse device used in the treatment of keloid and hypertrophic scars at the American Society for Dermatologic Surgery Annual Meeting.
Data from this study should be released by the end of this year.
The key reasons this story is compelling are given in an H.C. Wainwright & Co. report.
Progress has been made in all areas, from testing the product to evaluating distributors.
This will help its customers access the products and tools they need more sustainably.
Akcea Therapeutics' shares are trading 30% higher today on news that it has entered into a worldwide exclusive licensing agreement with Pfizer for AKCEA-ANGPTL3-LRx used in the treatment of patients with cardiovascular and metabolic diseases.
Healthcare Tech Firm Expands Patient Base in Texas (10/04/2019)
The company landed five new U.S. facilities as customers.
This morning PDS Biotechnology Corp. shares are trading 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection.
Non-invasive medical device maker Zynex Inc's. shares are trading 12% higher on an overall down market day after the company reported that Q3/19 orders are up 95% over the same period in 2018.
|"From a stock perspective, 2019 was a clear breakout year for DRRX."|